Search | Virtual Health Library

1.

American Cancer Society prostate cancer survivorship care guidelines.

Skolarus, Ted A; Wolf, Andrew M D; Erb, Nicole L; Brooks, Durado D; Rivers, Brian M; Underwood, Willie; Salner, Andrew L; Zelefsky, Michael J; Aragon-Ching, Jeanny B; Slovin, Susan F; Wittmann, Daniela A; Hoyt, Michael A; Sinibaldi, Victoria J; Chodak, Gerald; Pratt-Chapman, Mandi L; Cowens-Alvarado, Rebecca L.

CA Cancer J Clin ; 64(4): 225-49, 2014.

Article in English | MEDLINE | ID: mdl-24916760

2.

A decision aid for teaching limitations of prostate cancer screening.

Weinrich, Sally P; Seger, Rachelle E; Rao, Ganesh S; Chan, Evelyn C; Hamm, Robert M; Godley, Paul A; Moul, Judd W; Powell, Isaac J; Chodak, Gerald W; Taylor, Kathryn L; Weinrich, Martin C.

J Natl Black Nurses Assoc ; 19(1): 1-11, 2008 Jul.

Article in English | MEDLINE | ID: mdl-18807773

3.

Combined androgen blockade in advanced prostate cancer: looking back to move forward.

Chodak, Gerald; Gomella, Leonard; Phung, De H.

Clin Genitourin Cancer ; 5(6): 371-8, 2007 Sep.

Article in English | MEDLINE | ID: mdl-17956709

4.

Critical review of complementary therapies for prostate cancer.

Wilkinson, Simon; Chodak, Gerald W.

J Clin Oncol ; 21(11): 2199-210, 2003 Jun 01.

Article in English | MEDLINE | ID: mdl-12775747

5.

[Usefulness and positioning of MAB therapy for prostate cancer].

Akaza, Hideyuki; Chodak, Gerald W; Hirao, Yoshihiko.

Gan To Kagaku Ryoho ; 32(10): 1507-20, 2005 Oct.

Article in Japanese | MEDLINE | ID: mdl-16227758

6.

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Schellhammer, Paul F; Chodak, Gerald; Whitmore, James B; Sims, Robert; Frohlich, Mark W; Kantoff, Philip W.

Urology ; 81(6): 1297-302, 2013 Jun.

Article in English | MEDLINE | ID: mdl-23582482

7.

Natural history of early localized prostate cancer.

Osborn, Jonathan R; Chodak, Gerald W.

JAMA ; 292(13): 1549; author reply 1549-50, 2004 Oct 06.

Article in English | MEDLINE | ID: mdl-15467049

8.

Editorial comment.

Chodak, Gerald W.

Urology ; 81(4): 852; discussion 852, 2013 Apr.

Article in English | MEDLINE | ID: mdl-23465167

9.

Do "rapid" PSA assays reduce anxiety and stress of prostate cancer patients undergoing regular review? A prospective evaluation.

Wilkinson, Simon; Warren, Katherine; Ramsden, Alistair; Matthews, Alicia; Chodak, Gerald.

Urology ; 71(4): 567-72, 2008 Apr.

Article in English | MEDLINE | ID: mdl-18387384

10.

Prostate cancer: epidemiology, screening, and biomarkers.

Chodak, Gerald.

Rev Urol ; 8 Suppl 2: S3-8, 2006.

Article in English | MEDLINE | ID: mdl-17021639

11.

Assessment of American urologists' approach to hormonal management of prostate cancer.

Warren, Katherine S; Osborn, Jonathan; Chodak, Gerald W.

Urology ; 68(6): 1305-7, 2006 Dec.

Article in English | MEDLINE | ID: mdl-17169651

12.

The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.

McLeod, David G; See, William A; Klimberg, Ira; Gleason, Donald; Chodak, Gerald; Montie, James; Bernstein, Gregory; Morris, Clive; Armstrong, Jonathon.

J Urol ; 176(1): 75-80, 2006 Jul.

Article in English | MEDLINE | ID: mdl-16753373

13.

Maximum androgen blockade: a clinical update.

Chodak, Gerald W.

Rev Urol ; 7 Suppl 5: S13-7, 2005.

Article in English | MEDLINE | ID: mdl-16985879

14.

Editorial comment.

Chodak, Gerald W.

Urology ; 75(5): 1027-8; author reply 1028, 2010 May.

Article in English | MEDLINE | ID: mdl-20451710

15.

A critical review of maximal androgen blockade for advanced prostate cancer.

Chodak, Gerald W.

Rev Urol ; 6 Suppl 8: S18-23, 2004.

Article in English | MEDLINE | ID: mdl-16985916

16.

An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.

Wilkinson, Simon; Chodak, Gerald.

Eur Urol ; 45(5): 581-4; discussion 585, 2004 May.

Article in English | MEDLINE | ID: mdl-15082199

17.

The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.

Wilkinson, Simon; Chodak, Gerald.

J Urol ; 172(1): 133-6, 2004 Jul.

Article in English | MEDLINE | ID: mdl-15201753

18.

Educating African-American men about prostate cancer: impact on awareness and knowledge.

Wilkinson, Simon; List, Marcy; Sinner, Michael; Dai, Lanting; Chodak, Gerald.

Urology ; 61(2): 308-13, 2003 Feb.

Article in English | MEDLINE | ID: mdl-12597936

19.

Attitudes and use of complementary medicine in men with prostate cancer.

Wilkinson, Simon; Gomella, Leonard G; Smith, Joseph A; Brawer, Michael K; Dawson, Nancy A; Wajsman, Zev; Dai, Lanting; Chodak, Gerald W.

J Urol ; 168(6): 2505-9, 2002 Dec.

Article in English | MEDLINE | ID: mdl-12441950

20.

Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.

Iversen, Peter; Wirth, Manfred P; See, William A; McLeod, David G; Klimberg, Ira; Gleason, Donald; Chodak, Gerald; Montie, James; Tyrrell, Chris; Wallace, D M A; Delaere, Karl P J; Lundmo, Per; Tammela, Teuvo L J; Johansson, Jan-Erik; Morris, Tom; Carroll, Kevin.

Urology ; 63(5): 928-33, 2004 May.

Article in English | MEDLINE | ID: mdl-15134983

Virtual Health Library

United States - Mexico Border

Your selection (0)

Export format:

Export:

American Cancer Society prostate cancer survivorship care guidelines.

A decision aid for teaching limitations of prostate cancer screening.

Combined androgen blockade in advanced prostate cancer: looking back to move forward.

Critical review of complementary therapies for prostate cancer.

[Usefulness and positioning of MAB therapy for prostate cancer].

Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.

Natural history of early localized prostate cancer.

Editorial comment.

Do "rapid" PSA assays reduce anxiety and stress of prostate cancer patients undergoing regular review? A prospective evaluation.

Prostate cancer: epidemiology, screening, and biomarkers.

Assessment of American urologists' approach to hormonal management of prostate cancer.

The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.

Maximum androgen blockade: a clinical update.

Editorial comment.

A critical review of maximal androgen blockade for advanced prostate cancer.

An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer.

The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.

Educating African-American men about prostate cancer: impact on awareness and knowledge.

Attitudes and use of complementary medicine in men with prostate cancer.

Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.